This document is an excerpt from the EUR-Lex website
Document 52021M10202
Prior notification of a concentration (Case M.10202 — EQT/Investindustrial/JV) Candidate case for simplified procedure (Text with EEA relevance) 2021/C 205/07
Prior notification of a concentration (Case M.10202 — EQT/Investindustrial/JV) Candidate case for simplified procedure (Text with EEA relevance) 2021/C 205/07
Prior notification of a concentration (Case M.10202 — EQT/Investindustrial/JV) Candidate case for simplified procedure (Text with EEA relevance) 2021/C 205/07
PUB/2021/413
OJ C 205, 31.5.2021, p. 9–10
(BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
31.5.2021 |
EN |
Official Journal of the European Union |
C 205/9 |
Prior notification of a concentration
(Case M.10202 — EQT/Investindustrial/JV)
Candidate case for simplified procedure
(Text with EEA relevance)
(2021/C 205/07)
1.
On 21 May 2021, the Commission received notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004. (1)This notification concerns the following undertakings:
|
— |
Igenomix, S.L.U. (‘Igenomix’, Spain), solely controlled by EQT AB (‘EQT’, Sweden); and |
|
— |
Universal Clinics, S.L. (‘Universal Clinics’, Spain), solely controlled by Investindustrial S.A. (‘Investindustrial’, Luxembourg). |
The proposed concentration consists of the acquisition of joint control, within the meaning of Article 3(1)(b) and 3(4) of the Merger Regulation, of a newly created joint venture (the ‘JV’) by EQT, through Igenomix, and Investindustrial, through Universal Clinics.
The concentration is accomplished by way of purchase of shares.
2.
The business activities of the undertakings concerned are:|
— |
for EQT: management of investment funds. Portfolio companies controlled by EQT include notably Igenomix, a company dedicated to the business of genetic and molecular diagnostics, as well as clinical and complementary analyses, specialized in the reproductive sector and in vitro fertilisation related testing; |
|
— |
for Investindustrial: management of investment funds. Portfolio companies controlled by Investindustrial include notably Universal Clinics, a company active in reproduction medicine through the ownership, operation and development of health clinics in Spain, Italy, Czech Republic and Sweden; |
|
— |
for the JV: development and commercialisation of a non-invasive embryo culture medical device to be used by in vitro fertilization laboratories. |
3.
On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the Merger Regulation. However, the final decision on this point is reserved.Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.
4.
The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:
M.10202 — EQT/Investindustrial/JV
Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:
Email: COMP-MERGER-REGISTRY@ec.europa.eu
Fax +32 22964301
Postal address:
|
European Commission |
|
Directorate-General for Competition |
|
Merger Registry |
|
1049 Bruxelles/Brussel |
|
BELGIQUE/BELGIË |
(1) OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).